NASDAQ$AIXC
AIxCrypto Holdings Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported an increase in FastPack sales and gross profit, strengthened product portfolio with milestone achievements and acquisition.
Qualigen Therapeutics reported increased revenues driven by FastPack sales, reduced net loss, and decreased research and development costs. They are progressing with their therapeutic pipeline and expanding their diagnostics business through strategic partnerships.
- FastPack sales increased by approximately 28% year-over-year.
- Gross profit on product sales was up 64% year-over-year.
- Net loss decreased by approximately 24% compared to the same quarter of the previous year.
- Company is on track to complete IND-enabling studies for QN-302 in Q3 and Q4 2022.
Headline financials
Revenue & EPS history
Qualigen · Revenue · Quarterly
$1.43M
Revenue by segment
Qualigen · $700K total across 1 segment · Q1 2022
- Product Sales$700K-50.0%100.0%
Forward guidance
Qualigen Therapeutics is focused on executing its strategy and achieving value-driving milestones for the remainder of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.6%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-8.3%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+18.8%
Q3 2016
Best reaction
-22.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +10.4% | -3.7% | -13.2% | |
| Q2 2025 | +6.8% | +7.1% | +19.0% | |
| Q1 2025 | +2.0% | -7.0% | -37.4% | |
| Q3 2024 | -12.6% | -6.3% | -6.1% | |
| Q2 2024 | -1.7% | +8.5% | -17.5% | |
| Q1 2024 | +5.7% | +68.7% | +41.6% | |
| Q4 2023 | +1.0% | -15.9% | -29.1% | |
| Q3 2023 | +4.5% | +2.4% | -14.7% | |
| Q2 2023 | +1.0% | +2.9% | -6.4% | |
| Q1 2023 | -5.9% | -3.8% | -5.9% | |
| Q4 2022 | +0.9% | +12.7% | +0.8% | |
| Q3 2022 | -4.5% | -3.2% | -35.5% | |
| Q2 2022 | -0.2% | -3.5% | -23.1% | |
| Q1 2022 | +5.4% | +0.0% | +20.8% | |
| Q4 2021 | -3.2% | -5.5% | -15.3% | |
| Q3 2021 | +0.9% | -6.1% | -9.0% | |
| Q2 2021 | -22.8% | -29.3% | -12.0% | |
| Q1 2021 | +17.6% | +20.3% | +46.4% | |
| Q4 2020 | +5.8% | +1.2% | -17.3% | |
| Q4 2019 | -14.0% | -13.5% | +6.9% | |
| Q3 2019 | -16.6% | -25.3% | -31.5% | |
| Q2 2019 | -1.4% | +4.1% | -64.5% | |
| Q1 2019 | -2.8% | -9.6% | -5.1% | |
| Q4 2018 | +10.0% | +9.4% | -10.7% | |
| Q3 2018 | -12.0% | -12.2% | -17.3% | |
| Q2 2018 | -2.4% | -5.9% | -18.5% | |
| Q1 2018 | +1.1% | +13.1% | +7.4% | |
| Q4 2017 | -4.9% | +2.7% | +9.3% | |
| Q3 2017 | -7.2% | -11.1% | -15.3% | |
| Q2 2017 | -4.4% | -6.7% | -2.5% | |
| Q1 2017 | -1.7% | -4.7% | -8.4% | |
| Q4 2016 | -11.4% | +6.6% | -44.6% | |
| Q3 2016 | +18.8% | +25.0% | +23.1% | |
| Q2 2016 | +1.5% | -2.3% | +4.6% | |
| Q1 2016 | -2.8% | — | — | |
| Q3 2015 | -4.7% | — | — | |
| Q2 2015 | -13.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro